SynAct Pharma AB (publ) (“SynAct”) today announced the program for the upcoming Capital Markets Day in Stockholm on May 5, 2023, for investors, analysts and media. The Capital Markets Day will feature presentations from SynAct’s management team and pre-clinical and clinical experts to provide an in-depth overview of the company’s development programs.
The agenda will be as follows:
| Program | ||
| 13:00 | Introduction | CEO Jeppe Øvlesen |
| Corporate update | Chairman Torbjørn Bjerke | |
| 13:15 | Melanocortin receptors and inflammation resolution | Professor Mauro Perretti |
| SynAct pre-clinical MC peptides | CSO Thomas Jonassen | |
| Q&A Session (break after QA session) | ||
| 14:30 | AP1189 program updates | CSO Thomas Jonassen |
| Unmet needs in RA around DMARD therapies | Rheumatologist Clinician | |
| AP1189 positioning and opportunity in RA and beyond | CBO Jim Knight | |
| Q&A Session | ||
| Wrap-up – SynAct on the move | Chairman Torbjørn Bjerke | |
| 16:00 | Reception |
The Capital Markets Day will be held at GT30 Grev Ture in Stockholm and be accessible through a webcast via the company’s website and via https://financialhearings.com/event/46621. The program will be held in English and run from 13:00 to 16:00 CEST. The presentations will be available on the company’s website after the event.
If you wish to attend, please register now via email to: [email protected].
The information was submitted, through the agency of the contact person below, for publication at 08:00 a.m CEST on April 17, 2023